Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
17 avr. 2023 13h30 HE
|
Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 avr. 2023 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
BioNTech und DualityBio schließen globale strategische Kollaboration – beschleunigte Entwicklung von differenzierten Antikörper-Wirkstoff-Konjugaten zur Therapie von soliden Tumoren im Fokus
03 avr. 2023 06h45 HE
|
BioNTech SE
BioNTech erhält von DualityBio exklusive, globale Lizenzen für zwei sich in der Entwicklung befindenden Antikörper-Wirkstoff-Konjugate (DB-1303 und DB-1311); die Kandidaten richten sich gegen...
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
03 avr. 2023 06h45 HE
|
BioNTech SE
BioNTech receives exclusive licenses from DualityBio for two investigational antibody-drug conjugate assets (DB-1303 and DB-1311) directed against targets expressed in a broad range of human...
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023
14 mars 2023 17h58 HE
|
Mablink
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR Annual Meeting 2023 In vivo antitumor efficacy with significant tumor growth inhibition in multiple...
Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023
09 mars 2023 04h00 HE
|
Oxford BioTherapeutics
Engine will combine OBT’s internationally recognised target discovery and ADC development capabilitiesOBT will also present a case study and two abstracts focussing on its recent novel target...
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
07 mars 2023 18h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
02 mars 2023 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...